Recent positive Phase 3 data from the Moderna-Merck personalized mRNA cancer vaccine partnership, announced August 19, 2026, showed the combination with Keytruda significantly reduced melanoma recurrence risk, driving Moderna shares sharply higher while reinforcing their collaborative model over outright acquisition. Merck’s separate 2026 deals for Terns Pharmaceuticals and Cidara Therapeutics highlight its active business development focus elsewhere, with no regulatory filings or disclosures signaling a Merck-Moderna merger. The 80.5% market-implied probability for no 2026 announcement reflects trader consensus on sustained partnership economics, high antitrust and integration barriers for large pharma-biotech combinations, and the absence of catalysts such as Keytruda patent cliffs prompting a full takeover. Upcoming Phase 3 readouts in additional tumor types could further entrench the existing alliance structure.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
20% probabilità
NUOVO
NUOVO
31 dic 2026
Sì
20% probabilità
NUOVO
NUOVO
31 dic 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data from the Moderna-Merck personalized mRNA cancer vaccine partnership, announced August 19, 2026, showed the combination with Keytruda significantly reduced melanoma recurrence risk, driving Moderna shares sharply higher while reinforcing their collaborative model over outright acquisition. Merck’s separate 2026 deals for Terns Pharmaceuticals and Cidara Therapeutics highlight its active business development focus elsewhere, with no regulatory filings or disclosures signaling a Merck-Moderna merger. The 80.5% market-implied probability for no 2026 announcement reflects trader consensus on sustained partnership economics, high antitrust and integration barriers for large pharma-biotech combinations, and the absence of catalysts such as Keytruda patent cliffs prompting a full takeover. Upcoming Phase 3 readouts in additional tumor types could further entrench the existing alliance structure.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Mercato aperto: Aug 19, 2026, 3:58 PM ET
Volume
$80Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data from the Moderna-Merck personalized mRNA cancer vaccine partnership, announced August 19, 2026, showed the combination with Keytruda significantly reduced melanoma recurrence risk, driving Moderna shares sharply higher while reinforcing their collaborative model over outright acquisition. Merck’s separate 2026 deals for Terns Pharmaceuticals and Cidara Therapeutics highlight its active business development focus elsewhere, with no regulatory filings or disclosures signaling a Merck-Moderna merger. The 80.5% market-implied probability for no 2026 announcement reflects trader consensus on sustained partnership economics, high antitrust and integration barriers for large pharma-biotech combinations, and the absence of catalysts such as Keytruda patent cliffs prompting a full takeover. Upcoming Phase 3 readouts in additional tumor types could further entrench the existing alliance structure.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$80Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Recent positive Phase 3 data from the Moderna-Merck personalized mRNA cancer vaccine partnership, announced August 19, 2026, showed the combination with Keytruda significantly reduced melanoma recurrence risk, driving Moderna shares sharply higher while reinforcing their collaborative model over outright acquisition. Merck’s separate 2026 deals for Terns Pharmaceuticals and Cidara Therapeutics highlight its active business development focus elsewhere, with no regulatory filings or disclosures signaling a Merck-Moderna merger. The 80.5% market-implied probability for no 2026 announcement reflects trader consensus on sustained partnership economics, high antitrust and integration barriers for large pharma-biotech combinations, and the absence of catalysts such as Keytruda patent cliffs prompting a full takeover. Upcoming Phase 3 readouts in additional tumor types could further entrench the existing alliance structure.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti